BRPI0518013A - inibidores de proteìna tirosina fosfatase, composição farmacêutica, complexo e métodos de uso dos mesmos - Google Patents

inibidores de proteìna tirosina fosfatase, composição farmacêutica, complexo e métodos de uso dos mesmos

Info

Publication number
BRPI0518013A
BRPI0518013A BRPI0518013-9A BRPI0518013A BRPI0518013A BR PI0518013 A BRPI0518013 A BR PI0518013A BR PI0518013 A BRPI0518013 A BR PI0518013A BR PI0518013 A BRPI0518013 A BR PI0518013A
Authority
BR
Brazil
Prior art keywords
protein tyrosine
tyrosine phosphatase
complex
pharmaceutical composition
methods
Prior art date
Application number
BRPI0518013-9A
Other languages
English (en)
Inventor
Mark A Blaslkovich
Ted Baughman
Thomas Little
William Patt
Maher Qabar
Lauri Schultz
Feng Hong
Gangadhar Nagula
Jennifer Lynn Gage
James Jeffry Howbert
Original Assignee
Ceptyr Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceptyr Inc filed Critical Ceptyr Inc
Publication of BRPI0518013A publication Critical patent/BRPI0518013A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/6541—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

INIBIDORES DE PROTEìNA TIROSINA FOSFATASE, COMPOSIçãO FARMACêUTICA, COMPLEXO E MéTODOS DE USO DOS MESMOS. A presente invenção refere-se a compostos de Fórmula (I) e Fórmula (II) que são úteis para modular a atividade biológica da enzima proteína tirosina fosfatase-1 b (PTP1 6). Compostos desta invenção podem ser empregados para tratar doenças e/ou condições em que a enzima PTP1 B é um fator. Tais doenças e/ou condições incluem, mas não são limitadas a, diabetes Tipo 1, diabetes Tipo 2, tolerância à glicose inadequada, resistência à insulina, obesidade, hiperlipidemia, hipertrigliceridemia, hipercolesterolemia, níveis de HDL baixos, aterosclerose, restenose vascular, doença do intestino inflamatória, pancreatite, tumores de célula adiposa, carcinoma de célula adiposa, lipossarcoma, dislipidemia, câncer e doenças neurodegenerativas.
BRPI0518013-9A 2004-11-15 2005-11-15 inibidores de proteìna tirosina fosfatase, composição farmacêutica, complexo e métodos de uso dos mesmos BRPI0518013A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62823304P 2004-11-15 2004-11-15
US70881705P 2005-08-15 2005-08-15
PCT/US2005/041269 WO2006055525A2 (en) 2004-11-15 2005-11-15 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0518013A true BRPI0518013A (pt) 2008-10-21

Family

ID=36407681

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518013-9A BRPI0518013A (pt) 2004-11-15 2005-11-15 inibidores de proteìna tirosina fosfatase, composição farmacêutica, complexo e métodos de uso dos mesmos

Country Status (9)

Country Link
US (3) US7504389B2 (pt)
EP (1) EP1812012A4 (pt)
JP (1) JP2008520575A (pt)
CN (1) CN101094677A (pt)
AU (1) AU2005306612B2 (pt)
BR (1) BRPI0518013A (pt)
CA (1) CA2586363A1 (pt)
NZ (1) NZ554783A (pt)
WO (1) WO2006055525A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503490A (ja) * 2004-06-17 2008-02-07 センジェント・セラピューティクス・インコーポレイテッド チロシンホスファターゼの三置換窒素調節物質
WO2006017124A2 (en) * 2004-07-09 2006-02-16 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
CA2675142C (en) * 2007-01-26 2014-08-19 Merck Frosst Canada Ltd. Fused aromatic difluoromethanephosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors
DE102007012284A1 (de) * 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035334A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007042154A1 (de) * 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
US8445706B2 (en) * 2008-09-05 2013-05-21 Board Of Trustees Of Northern Illinois University Unnatural amino acids capable of covalently modifying protein phosphatases and their use as general and specific inhibitors and probes
WO2011057331A1 (en) * 2009-11-11 2011-05-19 Monash University A method for treating obesity
CA2791535C (en) 2010-03-03 2018-05-22 The Governors Of The University Of Alberta Methods and systems for preparing irreversible inhibitors of protein tyrosine phosphatases
CN103788128A (zh) * 2014-01-22 2014-05-14 山西大学 一种有机膦四核铜配合物及其制备方法和应用
EP3110824A4 (en) * 2014-02-28 2017-11-29 The Royal Institution for the Advancement of Learning / McGill University Tc-ptp inhibitors as apc activators for immunotherapy
US20170296561A1 (en) * 2014-09-25 2017-10-19 Cold Spring Harbor Laboratory Treatment of rett syndrome
CN105037420B (zh) * 2015-08-13 2017-03-08 转化医学研究院（深圳）有限公司 一种芳羰基取代磷酸酯类化合物的合成方法
EP3456725A1 (en) * 2017-09-13 2019-03-20 Freie Universität Berlin Pentafluorophosphate derivative, its uses and an appropriate manufacturing method
CN110317230B (zh) * 2018-03-30 2023-11-07 上海昇悦医药科技有限公司 磷酸盐类衍生物及其用途
CN114920651A (zh) * 2022-06-28 2022-08-19 吉尔多肽生物制药(大连市)有限公司 一种(s)-4,4-二甲基-2-戊胺盐酸盐的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
WO1994008600A1 (en) * 1992-10-09 1994-04-28 Joslin Diabetes Center Inhibition of signal transduction molecules
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
GB9517060D0 (en) * 1995-08-17 1995-10-25 Ciba Geigy Ag Acylated oligopeptide derivatives
US6136798A (en) * 1996-05-16 2000-10-24 Warner-Lambert Company Compounds inhibiting the association of the PDGF receptor and phosphatidylinositol 3-kinase and their use
CA2269637A1 (en) * 1996-11-04 1998-05-14 Merck Frosst Canada & Co. Ligands for phosphatase binding assay
JP2001508647A (ja) * 1996-11-04 2001-07-03 メルク フロスト カナダ アンド カンパニー ヒドロラーゼ結合アッセイ
US6348572B1 (en) * 1996-11-12 2002-02-19 Merck Frosst Canada & Co. Ligands for phosphatase binding assay
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6225329B1 (en) * 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
WO1999046268A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
EP1064289A1 (en) * 1998-03-18 2001-01-03 Ariad Pharmaceuticals, Inc. Heterocyclic signal transduction inhibitors, compositions containing them
US6174874B1 (en) * 1998-09-21 2001-01-16 Merck Frosst Canada & Co. Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)
US20020055463A1 (en) * 1998-12-24 2002-05-09 Christiane Garbay Pseudopeptide compounds having an inhibiting activity with respect to paths activated by proteins with active tyrosine kinase activity and pharmaceutical compositions containing same
AU4738600A (en) * 1999-05-14 2000-12-05 Merck Frosst Canada & Co. Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1b (ptp-1b)
WO2001018013A1 (en) 1999-09-08 2001-03-15 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
RU2258707C2 (ru) 1999-12-03 2005-08-20 Де Риджентс ов де Юниверсити ов Калифорния, Сан-Диего Фосфонатные соединения
CA2393363A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
US6465444B2 (en) * 2000-03-22 2002-10-15 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
AU784462B2 (en) 2000-03-31 2006-04-06 Purdue Research Foundation Phosphoramidate prodrugs
WO2002102813A1 (en) * 2001-06-20 2002-12-27 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids for treatment of diabetes
US20040191926A1 (en) * 2001-09-26 2004-09-30 Zhong-Yin Zhang Ptp1b inhibitors and ligands
BR0309573A (pt) 2002-04-26 2005-02-01 Gilead Sciences Inc Acúmulo celular de análogos de fosfonato de compostos inibidores de hiv protease
US7214668B2 (en) 2002-05-13 2007-05-08 Metabasis Therapeutics, Inc. Phosphonic acid based prodrugs of PMEA and its analogues
US7193081B2 (en) 2002-05-13 2007-03-20 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of PMEA and PMPA
CA2517802A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein tyrosine phosphatase-prl-1 a a marker and therapeutic target for pancreatic cancer
JP2008503490A (ja) * 2004-06-17 2008-02-07 センジェント・セラピューティクス・インコーポレイテッド チロシンホスファターゼの三置換窒素調節物質
WO2006017124A2 (en) * 2004-07-09 2006-02-16 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases

Also Published As

Publication number Publication date
WO2006055525A2 (en) 2006-05-26
AU2005306612A1 (en) 2006-05-26
US20060142250A1 (en) 2006-06-29
EP1812012A4 (en) 2010-02-17
CA2586363A1 (en) 2006-05-26
US7829737B2 (en) 2010-11-09
US20080161592A1 (en) 2008-07-03
WO2006055525A3 (en) 2006-09-21
US20090131374A1 (en) 2009-05-21
AU2005306612B2 (en) 2010-12-16
JP2008520575A (ja) 2008-06-19
US7504389B2 (en) 2009-03-17
CN101094677A (zh) 2007-12-26
NZ554783A (en) 2010-12-24
EP1812012A2 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
BRPI0518013A (pt) inibidores de proteìna tirosina fosfatase, composição farmacêutica, complexo e métodos de uso dos mesmos
Khan et al. Stigmasterol protects rats from collagen induced arthritis by inhibiting proinflammatory cytokines
Yamazoe et al. Heterobifunctional molecules induce dephosphorylation of kinases–a proof of concept study
Maines et al. Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn’s disease
Baumli et al. The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508
MX2011006091A (es) Inhibidores de imidazopirazina syk.
BRPI0409916A (pt) ácidos carboxìlicos substituìdos com fenila
CL2008000020A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos.
CR20110016A (es) Compuestos quimicos 251
CY1115588T1 (el) Αναστολεις ανθρωπινης πρωτεϊνικης φωσφατασης τυροσινης-β και η φαρμακευτικη χρηση τους
NO20054769L (no) Substituerte fenylalkansyrer
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
Park et al. p27KIP1 is involved in ERK1/2-mediated MMP-9 expression via the activation of NF-κB binding in the IL-7-induced migration and invasion of 5637 cells
Olaoba et al. RAGE signaling in melanoma tumors
Kandhavelu et al. A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in colon cancer
Alqhtani et al. Inhibitory Mechanisms of β‐Glucuronidase by Hibiscus syriacus Phenolics: Integrating Computational and Experimental Approaches
Thompson et al. The role of senescent cells in acquired drug resistance and secondary cancer in BRAFi-treated melanoma
Kargbo Inhibitors of G12C mutant Ras proteins for the treatment of cancers
Tian et al. Decoding liver injury: a regulatory role for histone modifications
Yang et al. Emerging roles of post-translational modifications in skin diseases: current knowledge, challenges and future perspectives
BRPI0409497A (pt) métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite
Litman et al. A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway
Zi et al. A proteomic connectivity map for characterizing the tumor adaptive response to small molecule chemical perturbagens
Melchini et al. Enhanced in vitro biological activity of synthetic 2-(2-pyridyl) ethyl isothiocyanate compared to natural 4-(methylsulfinyl) butyl isothiocyanate
Mambelli et al. Phosphoethanolamine induces caspase-independent cell death by reducing the expression of C-RAF and inhibits tumor growth in human melanoma model

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2208 DE 30/04/2013.